TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

VECTICAL

CALCITRIOL
Immunology Approved 2009-01-23
2
Indications
--
Phase 3 Trials
17
Years on Market

Details

Status
Prescription
First Approved
2009-01-23
Routes
TOPICAL
Dosage Forms
OINTMENT

Companies

Active Ingredient: CALCITRIOL

VECTICAL Approval History

Loading approval history...

What VECTICAL Treats

1 indications

VECTICAL is approved for 1 conditions since its original approval in 2009. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Plaque Psoriasis
Source: FDA Label

Drugs Similar to VECTICAL

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AVAGE
TAZAROTENE
1 shared
ALMIRALL
Shared indications:
Plaque Psoriasis
BIMZELX
BIMEKIZUMAB-BKZX
1 shared
UCB INC
Shared indications:
Plaque Psoriasis
BRYHALI
HALOBETASOL PROPIONATE
1 shared
BAUSCH
Shared indications:
Plaque Psoriasis
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
BETAMETHASONE DIPROPIONATE
1 shared
SUN PHARMA CANADA
Shared indications:
Plaque Psoriasis
CIMZIA
CERTOLIZUMAB PEGOL
1 shared
UCB INC
Shared indications:
Plaque Psoriasis
CLOBEX
CLOBETASOL PROPIONATE
1 shared
GALDERMA LABS
Shared indications:
Plaque Psoriasis
CYLTEZO
ADALIMUMAB-ADBM
1 shared
Boehringer Ingelheim
Shared indications:
Plaque Psoriasis
DUOBRII
HALOBETASOL PROPIONATE
1 shared
BAUSCH
Shared indications:
Plaque Psoriasis
ENBREL
ETANERCEPT
1 shared
IMMUNEX
Shared indications:
Plaque Psoriasis
ENSTILAR
BETAMETHASONE DIPROPIONATE
1 shared
LEO PHARMA AS
Shared indications:
Plaque Psoriasis
HULIO
ADALIMUMAB-FKJP
1 shared
Viatris
Shared indications:
Plaque Psoriasis
HUMIRA
ADALIMUMAB
1 shared
AbbVie
Shared indications:
Plaque Psoriasis
IDACIO
ADALIMUMAB-AACF
1 shared
Fresenius Kabi
Shared indications:
Plaque Psoriasis
ILUMYA
TILDRAKIZUMAB-ASMN
1 shared
SUN PHARMA GLOBAL
Shared indications:
Plaque Psoriasis
IMPOYZ
CLOBETASOL PROPIONATE
1 shared
PRIMUS PHARMS
Shared indications:
Plaque Psoriasis
IMULDOSA
USTEKINUMAB-SRLF
1 shared
ACCORD BIOPHARMA INC.
Shared indications:
Plaque Psoriasis
OTEZLA
APREMILAST
1 shared
Amgen
Shared indications:
Plaque psoriasis
OTEZLA XR
APREMILAST
1 shared
Amgen
Shared indications:
Plaque Psoriasis
OTULFI
USTEKINUMAB-AAUZ
1 shared
Fresenius Kabi
Shared indications:
Plaque Psoriasis
PYZCHIVA
USTEKINUMAB-TTWE
1 shared
SAMSUNG BIOEPIS CO LTD
Shared indications:
Plaque Psoriasis
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

VECTICAL FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

VECTICAL Ointment is a vitamin D analog indicated for the topical treatment of mild to moderate plaque psoriasis in adult and pediatric patients 2 years and older. Limitations of Use The safety and effectiveness of VECTICAL Ointment in patients with known or suspected disorders of calcium metabolism have not been evaluated. 1.1 Indication VECTICAL Ointment is indicated for the topical treatment of mild to moderate plaque psoriasis in adults and pediatric patients 2 years and older. 1.2 Limitations of Use The safety and effectiveness of VECTICAL Ointment in patients with known or suspected diso...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.